Mirxes

#Mirxes is honoured to be part of last week’s NMRC (National Medical Research Council) Awards Ceremony and Research Symposium 2026, contributing to important conversations on the future of healthcare innovation in Singapore. We were privileged to have our Co-Founder and CEO, Dr Lihan Zhou, share his perspectives during the session on Innovative Technologies and Medical Entrepreneurship. Drawing from his journey as a scientist-turned-entrepreneur, he shared insights about building a publicly listed biotechnology company from Singapore despite the constraints of a small home market, and the importance of identifying the right innovations to advance in an increasingly dynamic and competitive healthcare landscape. On the exhibition floor, our SVP of Genomics, Dr Zhao Pan, showcased Mirxes’ advanced genomic and molecular testing capabilities, demonstrating how our technologies support earlier cancer detection, improve patient outcomes, and help more people live longer and healthier lives. We also welcomed Minister for Health Mr Ong Ye Kung’s announcement regarding the new S$350 million RIE (Research, Innovation and Enterprise) Grand Challenge on Maximising Healthy and Successful Longevity. The initiative closely aligns with Mirxes’ mission of advancing early disease detection, and we look forward to contributing towards innovations that can improve healthcare outcomes and create lasting impact for communities across Singapore. As NMRC celebrates 20 years of translational and clinical research excellence, we extend our warmest congratulations to all of this year’s award winners and researchers whose work continues to drive meaningful progress in healthcare. #precisionmedicine #biotech #earlydetection #miRNA #RNA #innovation #detectwithmirxes #healthcare #cancer #gastric #gastriccancer #lung #lungcancer #healthscreening #earlydetectionsaveslives

Gave the first of a series talk to the general staffs in #Mirxes last week on how to use #LLM better. While we have been working on #AI enabled products, and it’s been a great reminder that we also need to actively use these tools in our daily life. In our day-to-day work, the real effectiveness of AI usually comes down to the person using it. It’s rarely a one size fit all solution; it's more about developing the skill and mindset to integrate these tools into our daily habits to solve our own specific problems. #MiRXES #FutureOfWork #Innovation #Learning

Hear first-hand from Mirxes' Vikrant Kumar, Ph.D., whose extensive research experience spans the wide spectrum of genomics – from evolutionary to medical, and cancer genetics. The Harvard Medical School (HMS) Initiative for RNA Medicine (HIRM) is a leading research hub dedicated to accelerating the transition of non-coding RNA discoveries into transformative cancer diagnostics and therapeutics. Directed by Professor Frank Slack, and based at the Beth Israel Deaconess Medical Center, the initiative leverages a vast multi-disciplinary network to investigate how RNA molecules regulate gene expression in diseases like lung, breast, and prostate cancer. By housing a state-of-the-art Precision Diagnostics and Therapeutics Core Facility, HIRM provides the critical infrastructure needed to sequence, model, and deliver RNA-based solutions from the lab bench directly to the clinical bedside. #multiomics #genomics #biotech #precisionmedicine #earlydetection #miRNA #RNA #innovation #detectwithmirxes

#Mirxes is in an incredibly exciting scale-up phase, accelerating our mission to transform preventine medicine, from cancer early detection to multi-omics diagnostic solutions. We are looking for talents across ALL departments to help us reach the next level. Ready to make an impact in biotech? Explore our open roles below, and send your CV to hrsg@mirxes.com. #hiring #biotech #precisionmedicine #earlydetection #miRNA #RNA #innovation #detectwithmirxes

“We (Mirxes) are now looking ahead to the next phase — bringing our capability in developing and deploying RNA diagnostics in CAP-certified laboratory in Asia to partner with world-class oncology expertise and infrastructure in Boston. The work is becoming more real, and more urgent, by the year.” Dr Lihan Zhou, Co-Founder & CEO, Mirxes

𝗟𝗨𝗡𝗚𝗖𝗹𝗲𝗮𝗿 𝗚𝗮𝗶𝗻𝘀 𝗠𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗶𝗻 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 𝘃𝗶𝗮 𝐭𝐡𝐞 𝐒𝐄𝐇𝐀𝐓𝐢 𝐀𝐩𝐩 𝗮𝗻𝗱 𝗦𝘁𝗮𝘁𝗲-𝗟𝗲𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 We are pleased to share that our Malaysian JV, MyRNA, has made significant strides in expanding access to LUNGClear in Malaysia. Beginning last week, LUNGClear became available through 1,300 panel clinics integrated via the SEHATi app in the Klang Valley, with plans for nationwide expansion underway. 𝘚𝘌𝘏𝘈𝘛𝘪, 𝘢𝘯 𝘪𝘯𝘪𝘵𝘪𝘢𝘵𝘪𝘷𝘦 𝘱𝘰𝘸𝘦𝘳𝘦𝘥 𝘣𝘺 𝘗𝘌𝘙𝘒𝘌𝘚𝘖, 𝘪𝘴 𝘔𝘢𝘭𝘢𝘺𝘴𝘪𝘢'𝘴 𝘢𝘭𝘭-𝘪𝘯-𝘰𝘯𝘦 𝘥𝘪𝘨𝘪𝘵𝘢𝘭 𝘩𝘦𝘢𝘭��𝘩 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮. 𝘐𝘵 𝘣𝘳𝘪𝘯𝘨𝘴 𝘵𝘰𝘨𝘦𝘵𝘩𝘦𝘳 𝘢 𝘧𝘶𝘭𝘭 𝘳𝘢𝘯𝘨𝘦 𝘰𝘧 𝘩𝘦𝘢𝘭𝘵𝘩 𝘴𝘦𝘳𝘷𝘪𝘤𝘦𝘴 𝘧𝘳𝘰𝘮 𝘗𝘌𝘙𝘒𝘌𝘚𝘖-𝘧𝘶𝘯𝘥𝘦𝘥/𝘴𝘶𝘣𝘴𝘪𝘥𝘪𝘴𝘦𝘥 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘮𝘦𝘴 𝘵𝘰 𝘱𝘳𝘪𝘷𝘢𝘵𝘦 𝘤𝘢𝘳e 𝘰𝘱𝘵𝘪𝘰𝘯𝘴. 𝘗𝘌𝘙𝘒𝘌𝘚𝘖, 𝘰𝘳 𝘵𝘩𝘦 𝘚𝘰𝘤𝘪𝘢𝘭 𝘚𝘦𝘤𝘶𝘳𝘪𝘵𝘺 𝘖𝘳𝘨𝘢𝘯𝘪𝘴𝘢𝘵𝘪𝘰𝘯 (𝘚𝘖𝘊𝘚𝘖), 𝘪𝘴 𝘢 𝘔𝘢𝘭𝘢𝘺𝘴𝘪𝘢𝘯 𝘨𝘰𝘷𝘦𝘳𝘯𝘮𝘦𝘯𝘵 𝘢𝘨𝘦𝘯𝘤𝘺 𝘵𝘩𝘢𝘵 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘴𝘰𝘤𝘪𝘢𝘭 𝘴𝘦𝘤𝘶𝘳𝘪𝘵𝘺 𝘱𝘳𝘰𝘵𝘦𝘤𝘵𝘪𝘰𝘯 𝘵𝘰 𝘦𝘮𝘱𝘭𝘰𝘺𝘦𝘦𝘴. With fewer than 1 in 10 lung cancer patients in Malaysia surviving beyond five years due to late-stage diagnosis, early detection has never been more critical. LUNGClear is an innovative blood-based microRNA test designed for the early detection of lung cancer, providing a non-invasive and radiation-free solution for healthy individuals aged 40 and above who want to proactively monitor their lung health. 𝗦𝗰𝗮𝗹𝗶𝗻𝗴 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲 𝗦𝗲𝗹𝗮𝗻𝗴𝗼𝗿 𝗦𝗮𝗿𝗶𝗻𝗴 𝗣𝗶𝗹𝗼𝘁 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲 Beyond the SEHATi app, MyRNA is also supporting the Selangor Saring pilot initiative with LUNGClear. 𝘛𝘩𝘦 𝘚𝘦𝘭𝘢𝘯𝘨𝘰𝘳 𝘚𝘢𝘳𝘪𝘯𝘨 𝘪𝘴 𝘢 𝘴𝘵𝘢𝘵𝘦-𝘴𝘶𝘣𝘴𝘪𝘥𝘪𝘴𝘦𝘥 𝘩𝘦𝘢𝘭𝘵𝘩 𝘴𝘤𝘳𝘦𝘦𝘯𝘪𝘯𝘨 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘮𝘦 𝘭𝘢𝘶𝘯𝘤𝘩𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘚𝘦𝘭𝘢𝘯𝘨𝘰𝘳 𝘚𝘵𝘢𝘵𝘦 𝘎𝘰𝘷𝘦𝘳𝘯𝘮𝘦𝘯𝘵. 𝘐𝘵𝘴 𝘱𝘳𝘪𝘮𝘢𝘳𝘺 𝘰𝘣𝘫𝘦𝘤𝘵𝘪𝘷𝘦 𝘪𝘴 𝘵𝘩𝘦 𝘦𝘢𝘳𝘭𝘺 𝘥𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘯𝘰𝘯-𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘣𝘭𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴 (𝘕𝘊𝘋𝘴) 𝘢𝘯𝘥 𝘤𝘦𝘳𝘵𝘢𝘪𝘯 𝘤𝘢𝘯𝘤𝘦𝘳𝘴 𝘢𝘮𝘰𝘯𝘨 𝘳𝘦𝘴𝘪𝘥𝘦𝘯𝘵𝘴 𝘵𝘰 𝘦𝘯𝘢𝘣𝘭𝘦 𝘦𝘢𝘳𝘭𝘺 𝘪𝘯𝘵𝘦𝘳𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘮𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵, 𝘸𝘩𝘪𝘤𝘩 𝘤𝘢𝘯 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘩𝘦𝘢𝘭𝘵𝘩 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘢𝘯𝘥 𝘳𝘦𝘥𝘶𝘤𝘦 𝘭𝘰𝘯𝘨-𝘵𝘦𝘳𝘮 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘤𝘰𝘴𝘵𝘴. By integrating LUNGClear, the initiative moves towards a more precise, risk-stratified approach to screening, which facilitates: - Earlier identification of high-risk individuals. - More efficient use of diagnostic imaging resources. - Greater accessibility to community-based screening. These commercialisation milestones, currently in full momentum, are a testament to Mirxes’ unwavering commitment to delivering pioneering solutions for stakeholders and patients in Malaysia and beyond. Find out more about MyRNA and its developments here: https://myrna.my/

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗦𝗰𝗮𝗹𝗲 𝗗𝗶𝗴𝗲𝘀𝘁𝗶𝘃𝗲 𝗦𝘆𝘀𝘁𝗲𝗺 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗶𝗻 𝗖𝗵𝗶𝗻𝗮: 𝗧𝘄𝗼 𝗠𝗮𝗷𝗼𝗿 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲𝘀 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝗱 Mirxes’ clinical footprint in China marked a significant milestone at last week’s high-level “Xijiao Meeting” (High-Quality Development Academic Forum on Early Diagnosis and Treatment of Gastrointestinal Cancer) in Shanghai. At the event, we launched two strategic initiatives focused on gastric and colorectal cancer screening in China. These initiatives underscore a clear message: Mirxes is operating at full momentum with a focus on commercialisation at scale. Our dedication to the Chinese market and its "Healthy China 2030" national strategy remains unwavering, backed by the continued support of the country’s leading clinical leaders. 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗠𝗲𝗲𝘁𝘀 𝗨𝗻𝗺𝗲𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗡𝗲𝗲𝗱𝘀 These new initiatives address a critical gap in China’s healthcare landscape — where the burden of gastric and colorectal cancers is high, but screening accessibility remains a challenge. - “Protecting the Stomach in China" (护胃中国) Strategic Plan: This represents the largest real-world study of its kind in China. Leveraging our proprietary 12-miRNA gastric cancer biomarker technology, we are partnering with over 100 top-tier hospitals in China to build a standardised, scalable screening model for millions, and to provide robust real-world evidence to support national level reimbursement. - Colorectal Cancer (CRC) cfDNA Methylation Project: Utilising our global CADENCE multi-omics platform that integrate miRNA and methylation biomarkers, we are adapting our non-invasive blood-based screening tests for the Chinese population. Following the successful enrolment of over 6,000 participants in our Southeast Asian study, the Chinese validation project aims to enrol over 7,000 subjects to develop a high-sensitivity blood test alternative to colonoscopy. Through these initiatives, we aim to promote wider adoption of two-step (blood + endoscopy) screening method in China. By demonstrating long-term economic value and clinical impact, we are also establishing a clear trajectory towards national level reimbursement. 𝗩𝗼𝗶𝗰𝗲𝘀 𝗼𝗳 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗿𝗼𝗺 𝗘𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀 We are also honoured to have the guidance and endorsement of leading clinical leaders, proving the strength of our initiatives: - Academician Li Zhaoshen (Chinese Academy of Engineering): A pioneer in gastrointestinal health, he emphasised that Mirxes’ non-invasive technologies are "the key direction" to solving the challenge of mass screening in China, noting their significant clinical and social value. - Professor Li Xun (Vice President of Lanzhou University): He highlighted that Mirxes’ million-scale real-world study will provide the authoritative data needed to optimise national screening strategies and health resource allocation.

A massive shoutout to the 21 #Mirxes runners who ran on the National Stadium track over the weekend for the Singapore Cancer Society Relay For Life (RFL) 100KM Challenge! Split into three teams, our colleagues pushed through a gruelling 12-hour relay to complete the 100KM together. While the heat and humidity of Singapore made every KM a mental and physical battle, we kept one thought on our minds: the discomfort of a long-distance run is nothing compared to the journey cancer patients endure every day. At its heart, RFL celebrates life and the courage of cancer survivors. It is a powerful reminder that when a community rallies together, we can provide the support and funding needed for change. At Mirxes, our mission is clear: to save lives through early, actionable, and personalised diagnoses. Every KM covered by our team represents our unwavering commitment to this goal. We don’t just work in labs or offices; we are part of a global effort to change the narrative of cancer from one of fear to one of hope through early detection. Thank you to our runners for representing the Mirxes spirit and to everyone who supported the cause. Together, we keep moving forward! #precisionmedicine #biotech #earlydetection #miRNA #RNA #innovation #detectwithmirxes #healthcare #cancer #gastric #gastriccancer #lung #lungcancer #healthscreening #earlydetectionsaveslives #CSR #RFL

The recent sessions of the National People’s Congress (NPC) and the Chinese People’s Political Consultative Conference (CPPCC) have signalled a landmark shift in China’s healthcare landscape. As the 15th Five-Year Plan (2026-2030) takes shape, the central government has explicitly identified cancer early detection and screening as a top priority for the "Healthy China" initiative.  This high-level policy focus is set to catalyse China’s molecular diagnostics and precision medicine industry. By prioritising early intervention, the framework encourages a move away from late-stage treatment towards a proactive, technology-driven preventive public healthcare model. For the industry, this means a clearer regulatory path and increased integration of innovative screening technologies into the national healthcare ecosystem. In a policy-driven economy like China, a clear signal from the central government often serves as the definitive roadmap for market evolution. When the state identifies a strategic priority — such as cancer early detection — the entire ecosystem tends to pivot rapidly. This top-down direction typically triggers an influx of governmental resources, a surge in private investments, and an acceleration of market adoptions. 𝐅𝐢𝐫𝐬𝐭 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐜𝐮𝐫𝐞𝐦𝐞𝐧𝐭 𝐜𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐟𝐨𝐫 𝐆𝐀𝐒𝐓𝐑𝐎𝐂𝐥𝐞𝐚𝐫™ 𝐢𝐧 𝐂𝐡𝐢𝐧𝐚 At #Mirxes, we are encouraged to see our vision of "Stopping Cancer at an Early Stage" aligning with China’s national objectives. In a timely milestone, our China team has also secured our first government procurement contract for our flagship GASTROClear™ in Jiujiang, Jiangxi last week. Key Highlights: • Project Details: 2026 Lianxi District Gastric Cancer Screening and Early Intervention Project to provide screening services for 30,000 residents at a budget of RMB 8.1 million. • ⁠Technology: Utilising GASTROClear™, the first blood-based gastric cancer screening product to receive Class III Medical Device approval from China's NMPA. • Impact: This project also serves as a strategic model for integrating advanced biotechnology into public health systems, aiming to enhance local early detection rates and reduce the long-term disease burden.  𝐑𝐞𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠 𝐢𝐧 𝐒𝐢𝐧𝐠𝐚𝐩𝐨𝐫𝐞 Beyond this, with LUNGClear™ already commercialised in multiple markets across Asia-Pacific, we are preparing for the launch of CRC CADENCE (for colorectal cancer early detection) in Singapore and selected Southeast Asia markets in mid-2026. This follows the completion of the 6,000-participant enrollment for our clinical trial. Our commercial success in China and the broader region also allows us to reinvest resources into Singapore. By funding advanced R&D and hiring top-tier biotech talents, we are fostering a virtuous cycle that strengthens Singapore’s position as a global biotech hub 💪 #EarlyDetection #PublicHealth #HealthyChina2030 #Biotechnology #PrecisionMedicine #GASTROClear #RNA #miRNA #Cancer

#Mirxes AI Enablement & Bioinformatics Lead Dr Ah-Jung Jeon recently joined leaders from Google Cloud, Kyndryl, and Singapore Aero Engine Services Private Limited (SAESL) to discuss what it truly means to build an "AI-first" enterprise. At Mirxes, being AI-first isn't just about the technology; it’s about scaling responsibly to solve real-world healthcare challenges. Key takeaways from Dr Jeon's session: - Scaling Responsibly: In biotech, AI must be backed by rigorous governance and bioinformatics excellence. - Driving Outcomes: Whether it’s improving the sensitivity of cancer screening or streamlining complex data, the goal is measurable impact. - Culture First: Transitioning to an AI-first model requires a mindset shift across the entire organisation, from the lab to the boardroom. As we continue to pioneer miRNA-based technology, AI remains a critical engine in our mission to save lives through early detection. Watch the full discussion here: https://lnkd.in/gZa9WyNG #AI #innovation #precisionmedicine #biotech #earlydetection #miRNA #RNA #detectwithmirxes #healthcare #cancer #healthscreening #earlydetectionsaveslives